Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the ViiV’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors’ Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Matters identified that may affect the Company’s performance in the long term are set out in the principal risks disclosed above

ViiV Healthcare Limited
Corporate Governance and Section 172 statements for applicable UK subsidiaries

Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors’ Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Glaxo Operations UK Limited
GlaxoSmithKline UK Limited
GlaxoSmithKline Research & Development Limited
ViiV Healthcare Trading Services UK Limited
GlaxoSmithKline Intellectual Property Limited
GlaxoSmithKline Intellectual Property (No.2) Limited
GlaxoSmithKline Export Limited
GlaxoSmithKline Consumer Trading Services Limited
GlaxoSmithKline Services Unlimited
GlaxoSmithKline Consumer Healthcare (Overseas) Limited
Dealcyber Limited
Glaxo Group Limited
GlaxoSmithKline Caribbean Limited
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited
ViiV Healthcare UK Limited
ViiV Healthcare UK (No.3) Limited
GlaxoSmithKline UK Limited
GlaxoSmithKline Mercury Limited
GlaxoSmithKline Holdings (Ireland) Limited
SmithKline Beecham Research Limited
Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors’ Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Matters identified that may affect the Company’s performance in the long term are set out in the principal risks disclosed above.

GlaxoSmithKline Consumer Healthcare Finance No.2 Limited
GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited
GlaxoSmithKline Consumer Healthcare Sri Lanka Holdings Limited
PRISM PCH Limited
Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the TESARO UK Limited's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, as further detailed in the stakeholder engagement statements in the Directors’ Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Matters identified that may affect the Company’s performance in the long term are set out in the principal risks disclosed above.

Tesaro UK Limited
Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

GlaxoSmithKline Consumer Healthcare (UK) IP Limited
PHIVCO UK II Limited
BEECHAM GROUP P L C
Galvani Bioelectronics Limited
Wellcome Limited
ViiV Healthcare Overseas Limited
Stiefel Consumer Healthcare (UK) Limited
SmithKline Beecham Overseas Limited
SmithKline Beecham Limited
SmithKline Beecham (H) Limited
PHIVCO UK II Limited
Horlicks Limited
GlaxoSmithKline Consumer Healthcare Holdings Limited
GlaxoSmithKline Holdings (One) Limited
GlaxoSmithKline Holdings Limited
GlaxoSmithKline Intellectual Property Development Limited
GlaxoSmithKline Intellectual Property Holdings Limited
GlaxoSmithKline Intellectual Property Management Limited
Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes operate to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

Matters identified that may affect the Company’s performance in the long term are set out in the principal risks disclosed both above and in the Group’s 2019 Annual Report.

GlaxoSmithKline Finance plc
ViiV Healthcare Finance 2 Limited
Setfirst Limited
GlaxoSmithKline Investment Services Limited
GlaxoSmithKline Investment Holdings Limited
GlaxoSmithKline International Limited
GlaxoSmithKline Consumer Healthcare Finance Limited
GlaxoSmithKline IHC Limited
GSK Finance (No 2) Limited
GlaxoSmithKline Capital plc
Glaxochem (UK) Unlimited
Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes operate to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors’ Report and the feedback from the engagement has been considered by the Directors during the decision-making process. Matters identified that may affect the Company’s performance in the long term are set out in the principal risks disclosed above.

Consumer Healthcare Holdings Limited
Consumer Healthcare Intermediate Holdings Limited